The Journal of Practical Medicine ›› 2021, Vol. 37 ›› Issue (7): 835-838.doi: 10.3969/j.issn.1006⁃5725.2021.07.002

• Coronavirus（COVID-19） • Previous Articles     Next Articles

COVID ⁃19：hypercoagulability，thrombosis and anticoagulation

WANG Tongsheng，SU Xiuli，GAO Peng⁃ fei，CHU Xu，QIU Jiayong，MAO Yimin   

  1. Department of Respiratory Diseases，the First Affiliated Hospital，and Col⁃ lege of Clinical Medicine of He′nan University of Science and Technology，Luoyang 471003，China

  • Online:2021-04-10 Published:2021-04-10

Abstract:

Coronavirus Disease 2019（COVID⁃19）is caused by the new coronavirus SARS⁃CoV⁃2 and is characterized by an exaggerated inflammatory response. SARS ⁃CoV ⁃2 can trigger coagulopathy and thrombosis in patients with covid ⁃ 19. In severe cases，50% of the patients had coagulopathy. Up to 40% of patients still have deep vein thrombosis（DVT）and pulmonary embolism（PTE）. Low molecular weight heparin（LMWH）is recom⁃ mended as prophylactic anticoagulant therapy，Besides the Anticoagulant effect of LMWH，nonanticoagulant prop⁃ erties such as the reduction in interleukin 6 release and increasing the number of Limba cells，it can delay or block the inflammatory“cytokine storm”

Key words:

SARS?CoV?2, COVID?19, hypercoagulability, thrombosis, anticoagulation